Skip to content

SENS'REM - SENSoriality and Multi-Sensory Emotional Reminiscences: a Pilot Study

SENS'REM - SENSoriality and Multi-Sensory Emotional Reminiscences: Feasibility of Multi-Sensory Reminiscence in Virtual Reality on Apathy in Elderly People With Cognitive Disorders in Nursing Homes and Long-Term Care Units

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07468305
Acronym
SENS'REM
Enrollment
10
Registered
2026-03-12
Start date
2026-09-01
Completion date
2027-08-01
Last updated
2026-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apathy, Apathy in Dementia

Keywords

Neurocognitive disorders, apathy, dementia

Brief summary

SENS'REM is a pilot feasibility study evaluating a new non-drug therapeutic program based on multisensory reminiscence using immersive virtual reality in older adults living in nursing homes or long-term care units who present cognitive impairment and apathy. Apathy is a frequent symptom in people with neurocognitive disorders. It is characterized by a loss of motivation, reduced interest in activities, and decreased emotional engagement. Apathy strongly affects quality of life, social interactions, and participation in care, and current drug treatments have limited effectiveness. For this reason, non-pharmacological approaches are increasingly recommended. The SENS'REM program combines virtual reality with personalized multisensory stimulation (visual, auditory, olfactory and gustatory) to help participants relive meaningful autobiographical memories in an immersive and emotionally engaging environment. Each participant receives one session per week for six weeks. The content of the sessions is adapted to the individual life history of each participant. The primary objective of this study is to evaluate the feasibility of implementing this program in institutional settings, including recruitment, organization, technical aspects, and participant adherence. Secondary objectives include evaluating changes in apathy, quality of life, cognitive functioning, social engagement, participant satisfaction, and the tolerance of the intervention. The main hypothesis of the study is that a personalized multisensory virtual reality reminiscence program is feasible in nursing home and long-term care settings and may contribute to a reduction in apathy and an improvement in engagement and well-being among older adults with cognitive impairment. This pilot study will provide essential preliminary data to optimize the intervention and prepare a future larger comparative clinical trial.

Interventions

BEHAVIORALMultisensory Virtual Reality Reminiscence Intervention

Participants receive a personalized multisensory reminiscence therapy program delivered through immersive virtual reality. Each participant attends one individual session per week for six consecutive weeks. Sessions last between 30 and 60 minutes and are conducted in a quiet room within the nursing home or long-term care unit. The virtual environments are selected according to each participant's life history and personal memories, such as familiar places or meaningful contexts. The intervention combines visual immersion with auditory stimulation, olfactory cues, and, when appropriate, gustatory stimuli. During each session, participants are encouraged to express memories, emotions, and perceptions associated with the virtual experience. A trained investigator remains present throughout the session to ensure safety, provide support, and collect observational data. Sessions are adapted to the participant's tolerance and may be interrupted at any time. The intervention is designed to stim

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men or women aged 70 years or older * Living in a nursing home (EHPAD) or long-term care unit (USLD) for at least 3 months * Sufficient French language ability to understand the study procedures * Presence of apathy confirmed by a positive score on the Apathy Inventory * Moderate cognitive impairment documented by a Montreal Cognitive Assessment (MoCA) score between 10 and 17 * Affiliated with a social security or health insurance system * Medical approval for virtual reality exposure (no contraindication) * Ability to provide informed consent, or consent provided by a legal representative or trusted person when applicable

Exclusion criteria

* "Diagnosed psychiatric disorder according to DSM-5 criteria (e.g., schizophrenia, bipolar disorder) * Severe or acute behavioral disturbances incompatible with study participation * Neurological comorbidities incompatible with virtual reality use (e.g., Lewy body disease, history of epilepsy) * Severe sensory impairment (vision, hearing, or olfaction) preventing participation * Known susceptibility to cybersickness based on the CyberSickness in Virtual Reality Questionnaire (CSQ-VR) * Presence of a cardiac pacemaker incompatible with virtual reality headset use * Withdrawal of informed consent at any time during the study"

Design outcomes

Primary

MeasureTime frameDescription
Overall feasibility of the multisensory virtual reality reminiscence intervention in institutional settingsat 12 monthsFeasibility is assessed through functional, organizational, technological, and recruitment indicators. Functional feasibility is defined as the proportion of participants completing at least 50% of planned sessions (minimum 3 of 6 sessions). Organizational feasibility includes the proportion of sessions conducted as scheduled, and the frequency and reasons for postponed or cancelled sessions. Technological feasibility evaluates the availability and proper functioning of virtual reality equipment, including hardware or software failures and technical issues. Recruitment feasibility is assessed by the number of screened participants, the number eligible, and the proportion providing informed consent. No standardized scale is used; feasibility is described using descriptive quantitative indicators.

Secondary

MeasureTime frameDescription
Change in apathy level measured by the Apathy Inventoryat 12 monthsThe change in apathy is assessed using the Apathy Inventory (AI; Robert et al., 2002), a validated instrument for neurocognitive disorders. Three complementary versions are used: patient version (8 items, score range 0-32), caregiver version (18 items, score range 0-72), and informant version (18 items, score range 0-72). Items are rated from 0 (never) to 4 (very often). Lower scores indicate greater apathy, while higher scores reflect better motivation and engagement. No formal cut-off score is applied; changes are evaluated by comparing baseline and post-intervention scores across the three sources.
Tolerance of the intervention assessed by cybersickness symptomsat 12 monthsTolerance is assessed using the CyberSickness in Virtual Reality Questionnaire (CSQ-VR; Kourtesis et al., 2023), a validated instrument measuring discomfort related to virtual reality exposure. The questionnaire includes 20 items assessing symptoms such as nausea, dizziness, visual disturbance, disorientation, and fatigue. Each item is rated from 0 (none) to 4 (severe), providing a total score reflecting cybersickness severity. Higher scores indicate greater discomfort. No validated clinical cut-off is defined; tolerance is evaluated by comparing symptom severity across sessions and at the end of the intervention period. In addition, all adverse events related to VR use are systematically recorded.

Countries

France

Contacts

CONTACTAnne-Julie Vaillant-Ciszewicz, PhD
vaillant-ciszewicz.aj@chu-nice.fr+33615938590
CONTACTFRANCESCA FRESCURA
frescura.f@chu-nice.fr06.51.68.18.31
PRINCIPAL_INVESTIGATORAnne-Julie Vaillant-Ciszewicz, PhD

Centre Hospitalier Universitaire de Nice

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 27, 2026